The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease – Study Protocol

Abigail Louise Higgins; Marco Toffoli; Stephen Mullin; Chiao-Yin Lee; Sofia Koletsi; Micol Avenali; Fabio Blandini; Anthony H V Schapira

doi:10.1101/2021.07.21.21260533

Abstract

Mutations in GBA which are causative of Gaucher disease in their biallelic form, are the most common genetic risk factor for Parkinson disease. The diagnosis of Parkinson disease relies upon clinically defined motor features which appear after irreversible neurodegeneration. Prodromal symptoms of Parkinson disease may provide a means to predict latent pathology, years before the onset of motor features. Previous work has reported prodromal features of Parkinson disease in GBA mutation carriers, however this has been insufficiently sensitive to identify those that will develop Parkinson disease. The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease (RAPSODI) study assesses a large cohort of GBA mutation carriers, to aid development of procedures for earlier diagnosis of Parkinson disease.

Summary Points

The therapeutic focus for Parkinson disease is currently symptomatic, rather than disease-modifying or neuroprotective.
Non-motor prodromal features of Parkinson disease may precede the motor symptoms required for clinical diagnosis by several years.
GBA mutations, which are associated with Gaucher disease in their biallelic form, have emerged as the most common genetic risk factor for Parkinson Disease.
GBA associated PD displays a slightly exaggerated phenotype, including earlier age of onset, enhanced cognitive decline, more severe affective disturbances, and a greater likelihood of manifesting REM Sleep Behaviour Disorder, hyposmia and autonomic dysfunction.
The RAPSODI GD study is an annual remote assessment which aims to define the clinical prodrome of PD in a large cohort of GBA mutation carriers, to accurately predict clinical diagnosis.
The secondary objectives of RAPSODI GD are to risk stratify homozygote and heterozygote GBA mutation carriers for PD risk, understand the variable penetrance of the GBA associated PD phenotype, and create a platform for the future evaluation of biomarkers of disease.
The putative implication of the RAPSODI GD study is to contribute towards earlier diagnosis of GBA associated PD, to provide a timeframe for delivering neuroprotective interventions.
Defining prodromal PD in GBA carriers may have wider implications for sporadic PD.

Competing Interest Statement

This study was funded by the MRC (MR/M006646/1), Cure Parkinson Trust, Kattan Trust, an investigator-initiated research grant (IIR-GBR-001110) provided by Shire International GmbH, a member of the Takeda group of companies, and by the joint efforts of The Michael J. Fox Foundation for Parkinsons Research (MJFF) and the Aligning Science Across Parkinsons (ASAP). MJFF administers the grant [ASAP-000420] on behalf of ASAP and itself. For the purpose of open access, the author has applied for a CC-BY public copyright licence to the Author Accepted Manuscript (AAM) version arising from this submission. AHVS is supported by the UCLH NIHR BRC.

Clinical Trial

No trial ID: The manuscript is a research protocol for a prospective study designed to aid in developing a novel diagnostic framework for individuals at risk of developing Parkinson disease, rather than a clinical trial.

Funding Statement

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

London, Queen Square Research Ethics Committee (REC reference: 15/LO/1155).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Author Contributions: Abigail Higgins drafted the manuscript. Marco Toffoli, Chiao-Yin Lee, Sofia Koletsi, Stephen Mullin, Micol Avenali, Fabio Blandini and Anthony H V Schapira reviewed and edited the draft.
Financial Disclosure: This study was funded by the MRC (MR/M006646/1), Cure Parkinson Trust, Kattan Trust, an investigator-initiated research grant (IIR-GBR-001110) provided by Shire International GmbH, a member of the Takeda group of companies, and by the joint efforts of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and the Aligning Science Across Parkinson’s (ASAP). MJFF administers the grant [ASAP-000420] on behalf of ASAP and itself. For the purpose of open access, the author has applied for a CC-BY public copyright licence to the Author Accepted Manuscript (AAM) version arising from this submission. AHVS is supported by the UCLH NIHR BRC.
Information Pertaining to Writing Assistance: No funding writing assistance has been used in the creation of this manuscript.
Ethical Disclosure: RAPSODI has been approved by London – Queen Square Research Ethics Committee (REC reference: 15/LO/1155).
Data Sharing Statement: Not Applicable

Data Availability

This is a complete methodology manuscript, therefore no data is reported.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.